Recent updates and news regarding WSI PBG
Be sure to check back frequently to keep up to date on the happenings at WSI PBG.
January 25, 2022
Foundation Medicine has approved leveraging WSI consulting services specifically relating to the Military Health Laboratory Services.
January 21, 2022
WSI will be attending the Society of Government Service Urologists (SGSU) next week representing multiple client urology product portfolios including QBioMed product Strontium 89 which can be used for relief of bone pain in patients with bone metastases.
January 14, 2022
WSI CEO, Richard Ryan, is pleased to announce that WSI has entered into a Master Service Agreement (MSA) with Karyopharm Therapeutics with the intent to support the promotion of their Oncology product line.
December 31, 2021
WSI has finalized an extended agreement to launch MedLite ID within the Federal Healthcare Systems. MedLite ID is an easy-to-use, disposable medical device that enables clinicians to accurately and efficiently identify the single medication infusion line for IV drug administration.
December 24, 2021
WSI has finalized an extended agreement to launch MedLite ID WSI VP of federal Sales, Tammy Pritchard, is excited to announce the expansion of the WSI Federal Sales and Account Management team which will add an additional 7 regions to the WSI federal field team.
December 17, 2021
Effective January 1, 2022 WSI will begin to support the awareness and value proposition for the Petros Pharmaceutical Erectile Dysfunction (ED) product portfolio which will include Stendra (avanafil tablets).
December 10, 2021
Antares Pharmaceuticals and WSI will partner to promote XYOSTED (weekly testosterone auto injector therapy) within the VA and Military healthcare systems effective January 1, 2022.
December 3, 2021
CEO, Richard Ryan, is honored to announce that WSI VA Key Account Managers will continue to represent Keytruda on behalf of Merck within the VA Healthcare System in 2022.